Proteasome inhibitors reduce thrombospondin-1 release in human dysferlin-deficient myotubes
- PDF / 3,757,373 Bytes
- 10 Pages / 595.276 x 790.866 pts Page_size
- 65 Downloads / 144 Views
(2020) 21:784
RESEARCH ARTICLE
Open Access
Proteasome inhibitors reduce thrombospondin-1 release in human dysferlin-deficient myotubes Esther Fernández-Simón1, Cinta Lleixà1, Xavier Suarez-Calvet1,2, Jordi Diaz-Manera1,2,3, Isabel Illa1,2,3, Eduard Gallardo1,2*† and Noemí de Luna1,2*†
Abstract Background: Dysferlinopathies are a group of muscle disorders causing muscle weakness and absence or low levels of dysferlin, a type-II transmembrane protein and the causative gene of these dystrophies. Dysferlin is implicated in vesicle fusion, trafficking, and membrane repair. Muscle biopsy of patients with dysferlinopathy is characterized by the presence of inflammatory infiltrates. Studies in the muscle of both human and mouse models of dysferlinopathy suggest dysferlin deficient muscle plays a role in this inflammation by releasing thrombospondin1. It has also been reported that vitamin D3 treatment enhances dysferlin expression. The ubiquitin-proteasome system recognizes and removes proteins that fail to fold or assemble properly and previous studies suggest that its inhibition could have a therapeutic effect in muscle dystrophies. Here we assessed whether inhibition of the ubiquitin proteasome system prevented degradation of dysferlin in immortalized myoblasts from a patients with two missense mutations in exon 44. Methods: To assess proteasome inhibition we treated dysferlin deficient myotubes with EB1089, a vitamin D3 analog, oprozomib and ixazomib. Western blot was performed to analyze the effect of these treatments on the recovery of dysferlin and myogenin expression. TSP-1 was quantified using the enzyme-linked immunosorbent assay to analyze the effect of these drugs on its release. A membrane repair assay was designed to assess the ability of treated myotubes to recover after membrane injury and fusion index was also measured with the different treatments. Data were analyzed using a one-way ANOVA test followed by Tukey post hoc test and analysis of variance. A p ≤ 0.05 was considered statistically significant. Results: Treatment with proteasome inhibitors and EB1089 resulted in a trend towards an increase in dysferlin and myogenin expression. Furthermore, EB1089 and proteasome inhibitors reduced the release of TSP-1 in myotubes. However, no effect was observed on the repair of muscle membrane after injury. Conclusions: Our findings indicate that the ubiquitin-proteasome system might not be the main mechanism of mutant dysferlin degradation. However, its inhibition could help to improve muscle inflammation by reducing TSP-1 release. Keywords: Dysferlin, Proteasome, Vitamin D3, Myogenin, Sarcolemma, Thrombospondin-1
* Correspondence: [email protected]; [email protected] † Eduard Gallardo and Noemí de Luna contributed equally to this work. 1 Neuromuscular Diseases group. Institut de Recerca Hospital de Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Universitat Autónoma de Barcelona, c/Sant Antoni Mª Claret 167, 08025 Barcelona, Spain Full list of author information is available at the end of
Data Loading...
